Abstract
Ketorolac, a NSAID routinely used during surgery proposed to have anticancer effects, is a promising way to improve postoperative oncological outcome. This effect may be particularly prominent in patients with elevated preoperative inflammatory scores, like the neutrophil:lymphocyte ratio. In this paper, we describe the rationale, the preliminary analyses in our patients, the feasibility and the methodology of a prospective randomized trial called “Ketorolac in Breast Cancer trial” (KBCt) (NCT01806259).
Original language | English |
---|---|
Pages (from-to) | 707-712 |
Number of pages | 6 |
Journal | Medical Hypotheses |
Volume | 81 |
Issue number | 4 |
Early online date | 9 Aug 2013 |
DOIs | |
Publication status | Published - Oct 2013 |
Bibliographical note
Financial supportThis work is financed by Reliable Cancer Therapies and supported by the Belgian Society of Anaesthesia and Resuscitation, the Fondation Saint-Luc, the Departments of Anesthesiology, and the Commission du Patrimoine of the Université catholique de Louvain, St-Luc Hospital.